Back to the Virtual Exhibit Hall

 

                                                                                                                                                                                                                                                                                                                 

Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical

Company pioneering novel cancer therapies and dedicated to the discovery,

development, and commercialization of novel first-in-class drugs for the

treatment of cancer and other diseases. Karyopharm's Selective Inhibitor

of Nuclear Export (SINE) compounds function by binding with and inhibiting

the nuclear export protein XPO1. https://www.karyopharm.com

Learn About Our Indications

Prescribing Information

Product Brochure

Product Information Fact Sheet

Patient Profiles

 

Gregg Stewart

Hematology/Oncology Specialist

Gregg.stewart@karyopharm.com

724-316-4448

 

 

 

 

 

 

 

 

  •